Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Pope

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
Archives of Dermatology|February 21, 2007
Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditionsGillian C de Gannes, Mehran Ghoreishi, Janet Pope, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
The Cochrane Database of Systematic Reviews|December 14, 2017
Calcium channel blockers for primary and secondary Raynaud's phenomenonFadumo Rirash, Paul C Tingey, Sarah E Harding, et al.
Clinical Rheumatology|February 8, 2007
The development of systemic sclerosis classification criteriaJennifer G Walker, Janet Pope, Murray Baron, et al.
RMD Open|January 27, 2017
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritisRoy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studiesTabitha N Kung, Jessica Dennis, Yiqing Ma, et al.
The Journal of Rheumatology|October 3, 2014
Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH)Bindee Kuriya, Juan Xiong, Gilles Boire, et al.
Rheumatology International|March 31, 2012
Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohortLauren Mussen, Tristan Boyd, Vivian Bykerk, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Patient perception of disease burden in diffuse cutaneous systemic sclerosisDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Archives of Dermatology|February 21, 2007
Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditionsGillian C de Gannes, Mehran Ghoreishi, Janet Pope, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
The Cochrane Database of Systematic Reviews|December 14, 2017
Calcium channel blockers for primary and secondary Raynaud's phenomenonFadumo Rirash, Paul C Tingey, Sarah E Harding, et al.
Clinical Rheumatology|February 8, 2007
The development of systemic sclerosis classification criteriaJennifer G Walker, Janet Pope, Murray Baron, et al.
RMD Open|January 27, 2017
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritisRoy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studiesTabitha N Kung, Jessica Dennis, Yiqing Ma, et al.
The Journal of Rheumatology|October 3, 2014
Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH)Bindee Kuriya, Juan Xiong, Gilles Boire, et al.
Rheumatology International|March 31, 2012
Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohortLauren Mussen, Tristan Boyd, Vivian Bykerk, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Patient perception of disease burden in diffuse cutaneous systemic sclerosisDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Pageof 17